Trial · NCT07240766
HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
NCT07240766, Phase 2, Recruiting, Zhejiang University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation. Trials, record NCT07240766. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07240766
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
- NCT number
- NCT07240766
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Zhejiang University
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma
- Interventions
- HRS-4642+AG+Nimotuzumab
- First posted
- 2025-11-21
- Last updated
- 2026-02-13
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 12-month Event-Free Survival (EFS) rate | Up to one year | The proportion of patients who had tumor progression, tumor recurrence (local, regional or distant) or death within 1 year after surgery, whichever occurred first |
| Secondary | Event Free Survival, EFS | Up to 2 years | From treatment to the date of the first documented tumor progression, tumor into recurrence or death from any cause, whichever occurred first |
| Secondary | Surgical resection rate | Up to 1 year | The proportion of patients who receive the radical resection |
| Secondary | R0 resection rate | Up to 1 year | R0 resection rate is the percentage of patients who undergo a surgical procedure where the surgeon successfully removes the entire visible tumor and a microscopic examination confirms that no cancer cells are left at the edges (margins) of the removed tissue. |
| Secondary | Pathological Complete Response (pCR) Rate | Up to 1 year | The percentage of patients who, after pre-surgical (neoadjuvant) therapy, have no viable cancer cells detected in the tumor tissue and lymph nodes that are removed during subsequent surgery when examined under a microscope by a pathologist. |
| Secondary | Major Pathological Response (MPR) Rate | Up to 1 year | The percentage of patients who, after neoadjuvant therapy, have only a minimal amount of viable tumor remaining in the resected specimen. This is typically defined as ≤10% |
| Secondary | Objective Response Rate (ORR) | Up to 2 years | The proportion of patients whose tumor shrinks (responds) by a predefined amount from its baseline size for a minimum period of time. It includes two categories of response: Complete Response (CR): The disappearance of all target tumors. Partial Response (PR): A specified minimum decrease (e.g., 30%) in the sum of the diameters of the target tumors. |
| Secondary | Disease Control Rate (DCR) | Up to 2 yeas | The proportion of patients who have achieved a best response of either Stable Disease (SD), Partial Response (PR), or Complete Response (CR). It essentially measures the treatment's ability to stop the cancer from growing. |
| Secondary | Overall Survival (OS) | Up to 3 yeas. | The length of time from a defined point in a study (e.g., date of randomization or start of treatment) until death from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07240766
GET https://conductscience.org/api/trials/v1/NCT07240766/registered